SGS and Bavarian Nordic to Develop a Challenge Model for Respiratory Syncytial Virus

Published on: 

Applied Clinical Trials

SGS has collaborated with Bavarian Nordic to develop a novel and differentiated challenge model for respiratory syncytial virus. This partnership brings both expertise and a view of wanting to bring a life changing therapy to the market. This new model will assist with the advancement of a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV.

Read the full release here.